November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Malvern Instruments
Dynamic light scattering system measures microrheology and protein structure


The Zetasizer Nano ZSP is an addition to the Malvern Instruments’ range of dynamic light scattering (DLS) systems. The Nano ZSP measures both size and zeta potential (i.e., electrophoretic mobility) of proteins. A new protein mobility measurement type in the software that controls data acquisition guides the user through the measurement and assesses and reports on data quality. The Nano ZSP uses a new version of Zetasizer software that enables microrheology measurements for the first time on Zetasizer instruments. This DLS-based optical technique allows rheological characterization of weakly-structured and highly strain-sensitive materials using only microliter sample volumes. Applications include measuring the viscosity of polymer and protein solutions and determining the onset of protein aggregation.


GEA Pharma Systems
Continuous high-shear granulation and drying system improves efficiency


The ConsiGma continuous high-shear granulation and drying system from GEA Pharma Systems uses continuous production technology instead of traditional batch technology to produce granules. The system is about one-fourth the size of a traditional granulation line and can run from 500 g for research and development up through production-size batches. Because it is a continuous process, larger amounts do not require a larger machine, but only a longer time. Eliminating scale-up helps reduce development time and cost. ConsiGma has been shown to improve intra-granular porosity and compressibility characteristics.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here